Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M, Crucitta S, Lorenzini G, De Angelis C, Diodati L, Cavallero D, Bargagna I, Cinacchi P, Fratini B, Salvadori B, Ghilli M, Roncella M, Fontana A, Danesi R, Cucchiara F. Del Re M, et al. Among authors: lorenzini g. Pharmacol Res. 2021 Jan;163:105241. doi: 10.1016/j.phrs.2020.105241. Epub 2020 Oct 10. Pharmacol Res. 2021. PMID: 33049397
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Del Re M, Crucitta S, Omarini C, Bargagna I, Mongillo M, Palleschi M, Stucci S, Meattini I, D'Onofrio R, Lorenzini G, Biondani P, De Giorgi U, Porta C, Livi L, Natalizio S, Fontana A, Giontella E, Angelini L, Fogli S, Danesi R. Del Re M, et al. Among authors: lorenzini g. Breast. 2022 Dec;66:157-161. doi: 10.1016/j.breast.2022.10.005. Epub 2022 Oct 15. Breast. 2022. PMID: 36283134 Free PMC article.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: lorenzini g. ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021 Sep 9. ESMO Open. 2021. PMID: 34509802 Free PMC article.
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Del Re M, et al. Among authors: lorenzini g. ESMO Open. 2022 Feb;7(1):100381. doi: 10.1016/j.esmoop.2022.100381. Epub 2022 Feb 4. ESMO Open. 2022. PMID: 35131649 Free PMC article. No abstract available.
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, Scalese M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G, Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D, Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. Coltelli L, et al. Among authors: lorenzini g. NPJ Breast Cancer. 2022 Mar 21;8(1):33. doi: 10.1038/s41523-022-00400-6. NPJ Breast Cancer. 2022. PMID: 35314692 Free PMC article.
Integrating ethics in AI development: a qualitative study.
Arbelaez Ossa L, Lorenzini G, Milford SR, Shaw D, Elger BS, Rost M. Arbelaez Ossa L, et al. Among authors: lorenzini g. BMC Med Ethics. 2024 Jan 23;25(1):10. doi: 10.1186/s12910-023-01000-0. BMC Med Ethics. 2024. PMID: 38262986 Free PMC article.
131 results